Immunic, Inc.
NASDAQ:IMUXBiotechnology
-$0.04 today
- Market cap
- $102.61M
- Beta
- 1.39
- P/E (TTM)
- -4.1
- EPS (TTM)
- -$3.46
Volume 0.17M
Average 0.27M
IMUX Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Immunic, Inc.NASDAQ: IMUX
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $33K fell 23.3% year over year, behind the +4.6% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 21.4% from the prior quarter. Over 3 fiscal years it compounded at +29.7% a year.
Context
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -23.3% toward the trailing-twelve-month pace of +4.6%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 168K USD
- Year-over-year change
- +25.4%
- 4-year CAGR
- +18.6%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 168K | +25.4% |
| FY2024 | 2024-12-31 | 134K | +20.7% |
| FY2023 | 2023-12-31 | 111K | +44.2% |
| FY2022 | 2022-12-31 | 77K | -9.4% |
| FY2021 | 2021-12-31 | 85K | — |
Depreciation & Amortization vs competitors
How IMUX compares with its peers on the latest reported figures
- IMUX's LTM Mar 2026 depreciation & amortization of $158K is the 7th highest of the 9 companies compared; the peer median is $2.14M.
- Its year-over-year change of +4.6% is the 2nd highest of 9, against a peer median of -18.1%.
- Over three fiscal years its annual growth of +29.7% compares with a peer median of +13.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.46M | -16.4% | +13.9% | 2.9% | |
| LTM Mar 2026 | $6.04M | -7.0% | +8.4% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $5.49M | -17.8% | +56.9% | 128.0% |
| LTM Mar 2026 | $2.88M | -18.4% | -17.7% | 31.5% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $1.39M | +27.4% | +55.0% | — |
| LTM Mar 2026 | $1.02M | -43.2% | +26.8% | — | |
| LTM Mar 2026 | $158K | +4.6% | +29.7% | — | |
| LTM Mar 2026 | $130K | -84.1% | -41.1% | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding IMUX) | $2.14M | -18.1% | +13.9% | 31.5% | |
Competitors are the stored peer set for IMUX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 61.12M | 71.26M | 83.22M | 80.05M | 81.98M |
| Selling, General & Admin | 13.3M | 15.26M | 16.01M | 18.01M | 21.25M |
| Operating Expenses | 91.67M | 119.49M | 99.22M | 98.05M | 103.23M |
| Depreciation & Amortization | 85K | 77K | 111K | 134K | 168K |
| EBITDA | (92.86M) | (86.44M) | (93.5M) | (100.37M) | (97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (91.67M) | (119.49M) | (99.22M) | (98.05M) | (103.23M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 66K | 1.04M | 3.08M | 3.39M | 1.04M |
| Interest Expense | 0 | 1.04M | 0 | 0 | 0 |
| Other Income / Expenses | (1.28M) | (919K) | 5.61M | (2.46M) | 6.06M |
| Income Before Tax | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (92.95M) | (120.41M) | (93.61M) | (100.51M) | (97.17M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| EPS (Diluted) | (39.20) | (37.80) | (21.10) | (10.00) | (6.24) |
| Weighted Avg Shares | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
| Weighted Avg Shares (Diluted) | 2.37M | 3.18M | 4.43M | 10.02M | 15.57M |
Immunic, Inc.
NASDAQ:IMUX
Intrinsic Alpha fair value
Locked
Current Price
$7.52
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.